Bing-Bing Wu1, Yi Yang1, Xiu Xu2, Wei-Ping Wang3. 1. Pediatrics Institute, Key Laboratory of Neonatal Diseases, Ministry of Health, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. 2. Department of Pediatric Healthcare, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. 3. Pediatrics Institute, Key Laboratory of Neonatal Diseases, Ministry of Health, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. wpwang@fudan.edu.cn.
Abstract
BACKGROUND: Intestinal microbiotas are thought to be the most important source of maturational stimuli to the development of the immune system. However, few studies have focused on the development of T helper (Th) 1 immune response and antibody response to vaccinations in healthy infants, especially in a large cohort. Through this randomized, double-blind control trial, we investigated the effects of Bifidobacterium longum BB536 (BB536) supplementation on intestinal microbiota composition and the immune response in term infants. METHODS: In total, 300 healthy newborns were recruited, randomized and fed formula either supplemented with BB536 or with no supplementation. Stool samples were analyzed at months 2, 4 and 11. The representative cytokine for Th1 [interferon-γ (IFN-γ)] and Th2 [interleukin-4 (IL-4)] secretion cells were measured using enzyme-linked immunospot assay at 4 and 7 months of age. The antibody response to vaccines was measured at months 7 and 11. RESULTS: A total of 264 infants completed the study. The amount of bifidobacteria and the bifidobacteria/ Enterobacteriaceae ratio (B/E) were significantly higher in the BB536 supplementation group at months 2 and 4. The number of IFN-γ secretion cells and the ratio of IFN-γ/IL-4 secretion cells were increased in the BB536 supplementation group at 7 months. Moreover, the higher value of B/E in the early stages seems to be related to the increased Th1 response. No difference was observed between groups in the antibody response after vaccination. CONCLUSION:BB536 has positive effects on establishing a healthy intestinal microbiota early in life, and it also plays an important role in improving the Th1 immune response.
RCT Entities:
BACKGROUND: Intestinal microbiotas are thought to be the most important source of maturational stimuli to the development of the immune system. However, few studies have focused on the development of T helper (Th) 1 immune response and antibody response to vaccinations in healthy infants, especially in a large cohort. Through this randomized, double-blind control trial, we investigated the effects of Bifidobacterium longumBB536 (BB536) supplementation on intestinal microbiota composition and the immune response in term infants. METHODS: In total, 300 healthy newborns were recruited, randomized and fed formula either supplemented with BB536 or with no supplementation. Stool samples were analyzed at months 2, 4 and 11. The representative cytokine for Th1 [interferon-γ (IFN-γ)] and Th2 [interleukin-4 (IL-4)] secretion cells were measured using enzyme-linked immunospot assay at 4 and 7 months of age. The antibody response to vaccines was measured at months 7 and 11. RESULTS: A total of 264 infants completed the study. The amount of bifidobacteria and the bifidobacteria/ Enterobacteriaceae ratio (B/E) were significantly higher in the BB536 supplementation group at months 2 and 4. The number of IFN-γ secretion cells and the ratio of IFN-γ/IL-4 secretion cells were increased in the BB536 supplementation group at 7 months. Moreover, the higher value of B/E in the early stages seems to be related to the increased Th1 response. No difference was observed between groups in the antibody response after vaccination. CONCLUSION:BB536 has positive effects on establishing a healthy intestinal microbiota early in life, and it also plays an important role in improving the Th1 immune response.
Entities:
Keywords:
T helper 1/T helper 2 balance; intestinal microbiota; probiotics supplementation; term infants; vaccination
Authors: E Bezirtzoglou; V Maipa; N Chotoura; E Apazidou; A Tsiotsias; C Voidarou; D Kostakis; A Alexopoulos Journal: Comp Immunol Microbiol Infect Dis Date: 2006-10-10 Impact factor: 2.268
Authors: Ji Yeun Kim; Jung Hyun Kwon; So Hyun Ahn; Sang Il Lee; Young Shin Han; Young Ok Choi; Soo Young Lee; Kang Mo Ahn; Geun Eog Ji Journal: Pediatr Allergy Immunol Date: 2009-10-14 Impact factor: 6.377
Authors: Andrea T Borchers; Carlo Selmi; Frederick J Meyers; Carl L Keen; M Eric Gershwin Journal: J Gastroenterol Date: 2009-01-22 Impact factor: 7.527
Authors: Shu E Soh; Dave Qi Rong Ong; Irvin Gerez; Xiaoe Zhang; Pavithra Chollate; Lynette Pei-Chi Shek; Bee Wah Lee; Marion Aw Journal: Vaccine Date: 2010-01-25 Impact factor: 3.641
Authors: M Nazmul Huda; Shaikh M Ahmad; M Jahangir Alam; Afsana Khanam; Karen M Kalanetra; Diana H Taft; Rubhana Raqib; Mark A Underwood; David A Mills; Charles B Stephensen Journal: Pediatrics Date: 2019-02 Impact factor: 7.124
Authors: Lenka Súkeníková; Viktor Černý; Jan Věcek; Petra Petrásková; Olga Novotná; Šimon Vobruba; Tereza Michalčíková; Jan Procházka; Libuše Kolářová; Ludmila Prokešová; Jiří Hrdý Journal: Cells Date: 2022-05-12 Impact factor: 7.666